AbbVie's liquidation posture as of March 31, 2026 is deeply negative, consistent with the MFFAIS-reported CLV of approximately -$105.6B. Total reported assets of $136.5B are dominated by intangibles ($50.9B net, zero recovery under liquidation lens) and goodwill ($35.6B, zero recovery), which together represent roughly 63% of total assets. Adjusting the remaining asset base for standard liquidation haircuts — cash at 100% ($9.4B), AR at 90-95% ($11.8-11.9B), inventory at 60% ($3.0B), PP&E at 50-70% ($2.8-4.0B) — yields recoverable tangible assets in the range of roughly $27-29B before other assets. Against this, total liabilities are carried at face: current liabilities of $42.1B (including $8.3B current portion of LTD and $33.8B accrued liabilities), long-term debt of $64.5B, and other non-current liabilities of $34.1B (which includes the $27.0B Level 3 contingent consideration liability at fair value — a face-value claim in liquidation regardless of fair value treatment). The contingent consideration alone at $27.0B exceeds the entire recoverable tangible asset base. The period saw AbbVie issue $8.0B of unsecured senior notes and repay $2.0B of a 364-day term loan, incrementally adding to the long-term debt stack. Financing activities were net positive at $919M due to the net new debt issuance, offset by $3.1B in dividends and $1.5B in buybacks. The retained earnings deficit deepened slightly to -$17.9B, and book equity is negative at -$6.7B (stockholders' interest). No impairment charges were recognized in Q1 2026. The $2.4B fair value increase in contingent consideration liabilities (driven by higher estimated Skyrizi sales and passage of time) expanded the Other Non-Current Liabilities balance, worsening the liquidation gap sequentially. The $744M in acquired IPR&D and milestones expense (primarily a $650M RemeGen upfront license payment) was expensed rather than capitalized, providing no asset value under the liquidation lens. The filing discusses litigation reserves of $1.7B and SG&A charges for higher litigation reserves in the period, though the aggregate litigation liability is not separately disclosed in XBRL with a distinct tag beyond what is embedded in accrued liabilities. Moody's upgraded ABBV to A2 in February 2026, which has no bearing on the liquidation recovery posture but does affect the company's ability to refinance the substantial debt stack.
▼ Community Notes